multiple myeloma

News

Janssen J&J Johnson and Johnson pharmaceutical companies

CHMP backs J&J's myeloma bispecific Tecvayli, ahead of US de...

The EMA's human medicines committee has recommended approval of Johnson & Johnson's Tecvayli as a fourth-line therapy for multip

News

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing a fu

News

J&J, Legend get EU nod for myeloma CAR-T Carvykti

Johnson & Johnson and Legend Biotech will arrive at next week's ASCO congress with a new EU approval for multiple myeloma CAR-T Carvykti.

Events

Partner Content

BCMA Targeted Therapies Summit

Revolutionize your BCMA pipeline

News

CHMP backs J&J's myeloma CAR-T therapy Carvykti

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA's human medicines commi

News

Blackstone funds new trials of Sanofi's Sarclisa in myeloma

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development

CHMP backs J&J's myeloma bispecific Tecvayli, ahead of US de...

ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

J&J, Legend get EU nod for myeloma CAR-T Carvykti

BCMA Targeted Therapies Summit

CHMP backs J&J's myeloma CAR-T therapy Carvykti

Blackstone funds new trials of Sanofi's Sarclisa in myeloma

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

multiple myeloma

Editor's Picks